Abstract
The p27Kip1(p27) protein is a cyclin-dependent kinase inhibitor of the transition from G1 to S phase. It has been reported that decreased p27 protein level is a negative prognostic indicator in human tumours including bladder cancer. We studied the relationship between protein levels of p27, cyclin E and Ki-67 and clinicopathological features of 145 consecutive Japanese patients with transitional cell carcinoma of the bladder using immunohistochemical staining. Low protein levels of p27 were associated with low staining of cyclin E (P = 0.0302), high Ki-67 index (P = 0.0306), poorly differentiated grade (P = 0.0006), muscle invasion (P = 0.0019) and lymph node metastsis (P = 0.0002). Low staining of cyclin E and high Ki-67 index correlated with poorly differentiated grade, muscle invasion and lymph node metastsis. Cyclin E protein levels was inversely related with Ki-67 index (P = 0.0002). Kaplan–Meier plots of survival rate in patients with low versus high p27 staining showed that low protein levels of p27 were associated with a shortened disease-free and overall survival (P< 0.0001 and P< 0.0001, respectively). Similarly, low staining of cyclin E and high Ki-67 index correlated with a shortened disease-free and overall survival. On multivariate analysis using Cox proportional hazards model, low protein levels of p27 and high Ki-67 index were independent predictors of shortened disease-free (P< 0.0001, P = 0.0031, respectively), and low protein levels of p27, low staining of cyclin E and high Ki-67 index of overall survival (P = 0.0017, P = 0.0009, P = 0.0003, respectively). In superficial bladder tumours (Ta, T1; 86 patients), significant correlations were observed between low p27 staining and high Ki-67 index and early recurrence (P = 0.0048, P = 0.0178, respectively). Among the recurrenced superficial tumours (35 patients), the tumours which remained at a low stage showed high protein levels of p27 and cyclin E, and the tumours which progressed to invasive disease showed a gradual decrease in p27 and cyclin E protein levels over time. Our findings suggest that decreased protein levels of p27 and cyclin E play a role in the progression of bladder cancer and to evaluate these protein levels may be useful in management of the diseases. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta I, Franssen E, Pritchard KI and Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein; prognostic implications in promary breast cancer. Nat Med 3: 227–230
Conner JP, Rpoportm F, Olsson CA, Sawczuk IS and Benson MC (1990) Long-term follow-up patients treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern. Urology 34: 353–356
Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z and Reuter VE (1992) Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251–1256
Del Pizzo JJ, Borkowski A, Jacobs SC and Kyprianou N (1999) Loss of cell cycle regulators p27Kip1and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 155: 1129–1136
Esposito V, Baldi A, Luka AD, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381–3385
Fujii Y, Fukui I, Kihara K, Tsujii T, Ishizaka K, Kageyama Y, Kawakami S and Oshima H (1998) Significance of bladder neck involvement on progression in superficial bladder cancer. Eur Urol 33: 464–468
Geller NL, Sternberg CN, Penenberg D, Scher H and Yagoda A (1991) Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy. Cancer 67: 1525–1531
Heney NM, Aiimed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD and Hwkins IR for national bladder cancer collaborative group A (1983) Superficial bladder cancer: Progression and recurrence. J Urol 130: 1083–1086
Hunter T and Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573–582
Kamai T, Takagi K, Asami H, Ito Y, Arai K and Yoshida K-I (2000) Prognostic significance of p27Kip1and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int 86: 14–19
Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH and Seth P (1997) Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57: 5441–5445
Keyomarsi K, Conte D, Toyofuku W and Fox MP (1995) Deregulation of cyclin E in breast cancer. Oncogene 11: 941–950
Kuczyk M, Machtens S, Hradil K, Schubach J, Christian W, Knüchel R, Hartmann J, Bokemeyer C, Jonas U and Serth J (1999) Predictive value of decreased p27Kip1protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 81: 1052–1058
Lamm DL, Riggs DR, Traynelis CL and Nseyo UO (1995) Apparent failure of current intravesical chemotherapy propphylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444–1450
Lee CCR, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishimoto T and Fukushima S (1997) Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 79: 780–789
Lee CCR, Ichihara T, Yamamoto S, Wanibuchi H, Sugimura K, Wada S, Kishimoto T and Fukushima S (1999) Reduced expression of the CDK inhibitor p27Kip1in rat two-stage bladder carcinogenesis and its association with expression profiles of p21WAF1/Cip1and p53. Carcinogenesis 20: 1697–1708
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup Jm and Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231–234
Loening S, Narayama A, Yoder L, Slymen D, Weinstein S, Penick G and Culp D (1980) Factors influencing the recurrence rate of bladder cancer. J Urol 123: 29–31
Logothetis CJ, Xu H-J, Ro JY, Hu S-X, Sahin A, Ordonez N and Benedict WF (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1256–1261
Masciullo U, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G and Giordano A (1999) Frequent loss of expression of the cyclin- dependent kinase inhibitor p27 in ovarian cancer. Cancer Res 59: 3790–3794
Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K and Akiyoshi T (1997) p27 expression and gastric carcinoma. Nat Med 3: 593
Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y and Cordon-Cardo C (1999) Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155: 105–113
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM (1997) Expression of cell- cycle regulators p27Kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 3: 222–225
Rakkar ANS, Li Z, Katayose Y, Kim M, Cowan KH and Seth P (1998) Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy. J Natl Cancer Inst 90: 1836–1838
Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP and Sauter G (2000) High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157: 787–794
Sgambato A, Migaldi M, Faraglia B, Garagnani L, Romano G, De Gaetani C, Ferrari P, Cpelli G, Trentini GP and Cittadini A (1999) Loss of p27Kip1expression correlates with tumor grade and with rduced disease-free survival in primary superficial bladder cancers. Cancer Res 59: 3245–3250
Shin KY, Kong G, Kim WS, Lee TY, Woo YN and Lee JD (1997) Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancer. Br J Cancer 75: 1786–1792
Sobin LH editors (1997) International union against cancer. TNM classification of malignant tumours, Geneva: UICC
Steeg PS and Abrams JS (1997) Cancer prognostics: past, present and p27. Nat Med 3: 152–154
Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ and Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403–407
Toyoshima H and Hunter T (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67–74
Tsihlias J, Kapusta L, Deboer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH and Slingerland JM (1998) Loss of cyclin-dependent kinase inhibitor p27Kip1is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58: 542–548
Vegt PDJ, Debruynr FMJ and van der Meijden APM (1995) Bacillus Calmette-Guerin in superficial bladder cancer: Consensus and controversies. Eur Urol 27: 89–95
Vlach J, Hennecke S and Amati B (1997) Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16: 5334–5344
Yang RM, Naitoh J, Murphy M, Wang H-J, Phillipson J, Dekernion JB, Loda M and Reiter RE (1998) Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941–945
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kamai, T., Takagi, K., Asami, H. et al. Decreasing of p27Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 84, 1242–1251 (2001). https://doi.org/10.1054/bjoc.2000.1736
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1736
Keywords
This article is cited by
-
Assessment of survivin and p27 expression as potential prognostic markers in urothelial cell carcinoma of urinary bladder in Egyptian patients
African Journal of Urology (2022)
-
PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein
Oncogene (2018)
-
Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report
BMC Cancer (2016)
-
Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer
Medical Oncology (2016)
-
p53 and retinoblastoma pathways in bladder cancer
World Journal of Urology (2007)